Valo Therapeutics Oy has successfully raised €19M in funding to further its research into novel cancer immunotherapies. The investment, primarily from European and Australian sources, is aimed at advancing the company's PeptiCRAd platform, which employs tumour antigen-coated viruses to stimulate immune responses against cancer. This funding will help support ongoing Phase 1B clinical trials across Italy, Australia, and Germany, and also contribute to establishing operations in Southern Italy. Valo's approach promises to simplify treatment strategies by avoiding the use of multiple genetically modified viruses, enhancing efficacy in targeting solid tumours.
Valo Therapeutics Oy, based in Helsinki, has raised €19M for advancing cancer immunotherapy technology, aiming to revolutionize treatment through innovative replication-competent virus vaccines.
With significant backing from both European and Australian investors, the company plans to expand its clinical trials and support patient treatments in multiple countries.
The PeptiCRAd platform enables the development of cancer treatments without necessitating multiple genetically modified viruses, enhancing systemic anti-tumour immune responses for solid tumours.
Utilizing funds from recent investments, Valo Therapeutics will advance its Phase 1B clinical study and address the manufacturing needs for its novel oncolytic virus candidates.
Collection
[
|
...
]